1. Scrip
  2. >>New Products

Nine Major Approval Decisions To Watch In Early 2022

 
• By Ayisha Sharma

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Exterior view of the headquarters of US Food and Drug Administration (FDA).
First Ever Approvals Are Expected For Some Indications. • Source: Alamy

Reata Pharmaceuticals, Inc.’s bardoxolone for chronic kidney disease due to Alport syndrome is expected to get a US Food and Drug Administration thumbs down by its 25 February PDUFA date, following a negative advisory committee vote in December. The regulator claimed Reata had not adequately shown the drug could slow progression of kidney function decline in Alport syndrome, a rare condition characterized by kidney disease, hearing loss and eye abnormalities. (Also see "Reata’s Bardoxolone Shot Down, But US FDA Advisors Offer Suggestions For Improved Study" - Pink Sheet, 9 December, 2021.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.